Spero与KKR附属公司达成1.05亿美元融资协议

• Spero Therapeutics (SPRO) said that it secured $105M in non-recourse, non-dilutive financing from affiliates of Healthcare Royalty, a business of KKR (KKR).
• The proceeds will primarily fund the Phase 2 development of SP001, Spero's lead immunology candidate, a third-generation anti-CD40L monoclonal antibody in-licensed from Innovent Biologics.
• Spero (SPRO)said the transaction strengthens its balance sheet and extends its expected cash runway into H2 2029.
• The stock price declined about 9% on Tuesday pre-market.

More on Spero Therapeutics

• Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering
• Spero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold)
• GSK, Spero win approval of Utebzi for complicated urinary tract infections
• Seeking Alpha’s Quant Rating on Spero Therapeutics
• Financial information for Spero Therapeutics